Published in Vaccine Weekly, July 7th, 2004
The fast track designation is intended to facilitate development and expedite the review of new therapies that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs so that an approved product can reach the market expeditiously.
Genetronics is currently conducting two phase III pivotal studies comparing the MedPulser System in combination with the cancer drug,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly